Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain [0.03%]
针对炎症痛的前列腺素E2信号通路靶向药物的研究进展
Sabine Grösch,Ellen Niederberger,Gerd Geisslinger
Sabine Grösch
Non-steroidal anti-inflammatory drugs (NSAID) are the most commonly used drugs for the treatment of pain, inflammation and fever. Although they are effective for a huge number of users, their analgesic properties are not sufficient for seve...
Steven B Bradfute
Steven B Bradfute
Jalal K Ghali
Jalal K Ghali
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects [0.03%]
一项针对健康受试者的随机双盲主动对照I期临床研究（VOLTAIRE-PK）比较了候选阿达木单抗生物类似药BI 695501与原研参照药的生物等效性、安全性和免疫原性
Christopher Wynne,Mario Altendorfer,Ivo Sonderegger et al.
Christopher Wynne et al.
Background: This Phase I study (VOLTAIRE®-PK) aimed to evaluate three-way pharmacokinetic similarity (bioequivalence), safety, and immunogenicity of BI 695501 (a Humira® [adalimumab] biosimilar candidate) compared with ...
Michele Fornaro,António E Nardi,Domenico De Berardis et al.
Michele Fornaro et al.
Psychotic features are common in bipolar disorder (BD), especially during acute mania. Even when early detected, their long-term management is difficult, essentially due to the unsatisfactory efficacy/tolerability profile of currently avail...
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer [0.03%]
叶酸受体α拮抗剂治疗上皮性卵巢癌的临床前和早期临床开发进展
Alice Bergamini,Simone Ferrero,Umberto Leone Roberti Maggiore et al.
Alice Bergamini et al.
The prognosis of patients affected by ovarian cancer has not substantially changed in the last decades and improving survival still remains a challenge. In the promising era of 'personalized therapy' several new biologic therapies are curre...
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV [0.03%]
临床前至II期临床开发用于治疗HIV的CCR5受体拮抗剂
Michelle B Kim,Kyle E Giesler,Yesim A Tahirovic et al.
Michelle B Kim et al.
The chemokine receptor CCR5 has garnered significant attention in recent years as a target to treat HIV infection largely due to the approval and success of the drug Maraviroc. The side effects and inefficiencies with other first generation...
Islam Y Elgendy,David E Winchester,Carl J Pepine
Islam Y Elgendy
Ischemic heart disease (IHD) is a major cause of death and disability among Western countries and angina pectoris is the most prevalent symptomatic manifestation. Strategies to improve management of chronic stable angina are a priority. Are...
Amanda J Brahm,Robert A Hegele
Amanda J Brahm
Severe genetic forms of hypertriglyceridemia carry a risk of life-threatening pancreatitis and lack available effective treatments. Lomitapide is a microsomal triglyceride transfer protein inhibitor currently approved for treatment of homoz...
C Genova,A Alama,S Coco et al.
C Genova et al.
Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the microtubule dynamics during cell cycle; this agent is currently available for previously treated advanced transitional cell carcinoma in Europe. The aim of this i...